Tranexaminezuur-13C6

Tranexamic acid-13C6 (Cyclocapron-13C6) is 13C labeled Tranexamic acid. Tranexamic acid (cyclocapron), a cyclic analog of lysine, is an orally active antifibrinolytic agent. Tranexamic acid attenuates the effects of severe trauma, inhibits urokinase plasminogen activator and ameliorates dry wrinkles. Tranexamic acid can used for the research of hemostasis [1][2][3][4][5].

Cyclocapron-13C6

12352211

AMPK; IGF-1R; Isotope-Labeled Compounds; Mitophagy; MMP

Autophagy; Epigenetics; Metabolic Enzyme/Protease; Others; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK

Cancer-Kinase/protease

Cancer; Neurological Disease; Cardiovascular Disease

O=C([13C@]1[13C][13C][13C@](CN)[13C][13C]1)O

C2 13C6H5NO2

153.09

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Prudovsky I, et al. Tranexamic acid suppresses the release of mitochondrial DNA, protects the endothelial monolayer and enhances oxidative phosphorylation [J]. Journal of cellular physiology, 2019, 234 (11) : 19121-19129.|[3]Wu G, et al. Tranexamic acid is an active site inhibitor of urokinase plasminogen activator [J]. Blood advances, 2019, 3 (5) : 729-733.|[4]Draxler D F, et al. Tranexamic acid modulates the cellular immune profile after traumatic brain injury in mice without hyperfibrinolysis [J]. Journal of Thrombosis and Haemostasis, 2019, 17 (12) : 2174-2187.|[5]Hiramoto K, et al. The amelioration effect of tranexamic acid in wrinkles induced by skin dryness [J]. Biomedicine & Pharmacotherapy, 2016, 80: 16-22.|[6]Sindet-Pedersen S, et al. Hemostatic effect of tranexamic acid mouthwash in anticoagulant-treated patients undergoing oral surgery [J]. New England Journal of Medicine, 1989, 320 (13) : 840-843.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-B0149S2/

Isotope-Labeled Compounds

No Development Reported